Wedbush Issues Negative Estimate for RARE Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Research analysts at Wedbush lowered their Q1 2025 earnings estimates for Ultragenyx Pharmaceutical in a research report issued to clients and investors on Wednesday, April 16th. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings per share of ($1.09) for the quarter, down from their prior forecast of ($1.06). Wedbush has a “Neutral” rating and a $48.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($0.86) EPS, Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($3.78) EPS, Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.81) EPS, FY2028 earnings at $1.91 EPS and FY2029 earnings at $3.20 EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). The firm had revenue of $164.88 million for the quarter, compared to the consensus estimate of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%.

A number of other equities analysts have also commented on the stock. JPMorgan Chase & Co. lifted their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an “overweight” rating in a report on Thursday, March 27th. HC Wainwright reiterated a “buy” rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Piper Sandler decreased their price target on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a research note on Monday, March 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. Finally, Canaccord Genuity Group increased their target price on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a “buy” rating in a research report on Tuesday, February 18th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $92.79.

Ultragenyx Pharmaceutical Price Performance

RARE opened at $35.69 on Friday. Ultragenyx Pharmaceutical has a fifty-two week low of $29.59 and a fifty-two week high of $60.37. The company’s 50 day moving average price is $38.41 and its two-hundred day moving average price is $44.18. The firm has a market capitalization of $3.35 billion, a price-to-earnings ratio of -5.63 and a beta of 0.61.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of large investors have recently modified their holdings of RARE. California State Teachers Retirement System grew its holdings in shares of Ultragenyx Pharmaceutical by 0.3% during the 4th quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company’s stock valued at $3,284,000 after purchasing an additional 268 shares during the last quarter. Van ECK Associates Corp boosted its position in Ultragenyx Pharmaceutical by 18.4% during the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 273 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in shares of Ultragenyx Pharmaceutical by 1.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock valued at $928,000 after buying an additional 294 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 76.2% in the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 323 shares during the period. Finally, BOKF NA increased its holdings in shares of Ultragenyx Pharmaceutical by 5.0% in the fourth quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company’s stock worth $336,000 after buying an additional 382 shares during the period. 97.67% of the stock is currently owned by institutional investors.

Insider Activity at Ultragenyx Pharmaceutical

In related news, EVP Karah Herdman Parschauer sold 2,990 shares of the business’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $42.88, for a total value of $128,211.20. Following the completion of the sale, the executive vice president now directly owns 54,991 shares of the company’s stock, valued at $2,358,014.08. The trade was a 5.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Thomas Richard Kassberg sold 6,028 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $253,778.80. Following the transaction, the executive vice president now directly owns 265,238 shares in the company, valued at approximately $11,166,519.80. This trade represents a 2.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 124,643 shares of company stock worth $5,256,268 in the last quarter. Company insiders own 5.50% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.